Drug Names Sep 13, 2022 ESMO Data Deepens Understanding of KRAS Inhibitor Activity in Lung, Colorectal Cancer Premium Sep 13, 2022 Imaging Agent May Have Potential as Noninvasive Test to Predict PARP Inhibitor Response Sep 13, 2022 Nearly all dMMR Colon Cancer Patients Respond in Trial of Neoadjuvant Opdivo-Yervoy Premium Sep 11, 2022 Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients Premium Sep 11, 2022 TIL Therapy Bests Yervoy in Head-to-Head Melanoma Trial; Will It Reach Patients Without Pharma? Premium Sep 10, 2022 Lynparza Presents Possibility of Cure for Some Patients With Biomarker-Defined Ovarian Cancer Premium Sep 10, 2022 Lilly's Verzenio Extends Five-Year Breast Cancer Survival, Adds to Debate Over Best CDK4/6 Inhibitor Sep 10, 2022 BMS Combo Drug Opdualag Effective in Neoadjuvant NSCLC, But Maybe No Better Than Opdivo Alone Premium Sep 8, 2022 Ivy Brain Tumor Center Using Novel Liquid Biopsy Technique to Track Brain Tumor Treatment Resistance Sep 7, 2022 NICE Finds Lynparza Not Cost-Effective in BRCA1/2-Mutated Advanced Prostate Cancer Sep 6, 2022 UK's MHRA Approves Adjuvant Lynparza for BRCA-Mutant, High-Risk Early Breast Cancer Sep 1, 2022 Aston Sci. to Launch Phase II US Study of Experimental Vaccine in HER2-Low Breast Cancer Patients Aug 31, 2022 Amgen's Lumakras Bests Chemo, Meets Primary Endpoint in CodeBreak 200 Trial Aug 29, 2022 Ideaya Reaches Milestone in Deal With GSK for Pol Theta Helicase Program Aug 26, 2022 Incyte's Pemazyre Nets FDA Approval for Rare Blood Cancer Aug 26, 2022 Melanoma Docs Resurrect PD-L1 Debate as CHMP, FDA Diverge on Opdualag Label Premium Aug 25, 2022 AstraZeneca's Tagrisso, Lynparza Net Adjuvant Approvals in Japan Aug 24, 2022 MMRF Data Fuels Greater Understanding of Multiple Myeloma Drug Resistance, Mutational Landscape Premium Aug 24, 2022 Roche Gets Expanded CE Mark for Ventana PD-L1 Assay to ID NSCLC Patients for Tecentriq Aug 17, 2022 Tessa Therapeutics Starts Trial of CAR T-Cell Therapy, BMS's Opdivo in Classical Hodgkin Lymphoma Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
